Landos Biopharma Stock Net Asset
| LABPDelisted Stock | USD 4.02 0.15 3.60% |
Landos Biopharma fundamentals help investors to digest information that contributes to Landos Biopharma's financial success or failures. It also enables traders to predict the movement of Landos Stock. The fundamental analysis module provides a way to measure Landos Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Landos Biopharma stock.
Landos |
Landos Biopharma Company Net Asset Analysis
Landos Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Landos Biopharma Net Asset | 38.04 M |
Most of Landos Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Landos Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Landos Biopharma has a Net Asset of 38.04 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Landos Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Landos Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Landos Biopharma could also be used in its relative valuation, which is a method of valuing Landos Biopharma by comparing valuation metrics of similar companies.Landos Biopharma is currently under evaluation in net asset category among its peers.
Landos Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.39 | |||
| Current Valuation | 42.67 M | |||
| Shares Outstanding | 3.13 M | |||
| Shares Owned By Insiders | 9.88 % | |||
| Shares Owned By Institutions | 52.04 % | |||
| Number Of Shares Shorted | 1.43 K | |||
| Price To Book | 2.11 X | |||
| Price To Sales | 2.37 X | |||
| Gross Profit | 18 M | |||
| EBITDA | (22.73 M) | |||
| Net Income | (21.93 M) | |||
| Cash And Equivalents | 55.75 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 27 K | |||
| Current Ratio | 8.91 X | |||
| Book Value Per Share | 7.43 X | |||
| Cash Flow From Operations | (20.48 M) | |||
| Short Ratio | 0.08 X | |||
| Earnings Per Share | (4.00) X | |||
| Target Price | 12.71 | |||
| Number Of Employees | 19 | |||
| Beta | 0.14 | |||
| Market Capitalization | 71.68 M | |||
| Total Asset | 38.04 M | |||
| Retained Earnings | (155.36 M) | |||
| Working Capital | 31.79 M | |||
| Net Asset | 38.04 M |
About Landos Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Landos Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Landos Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Landos Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Landos Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Landos Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Landos Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Landos Stock
Moving against Landos Stock
| 0.75 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.51 | EYE | National Vision Holdings | PairCorr |
| 0.48 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.46 | CVI | CVR Energy | PairCorr |
| 0.44 | LION | Lionsgate Studios Corp | PairCorr |
The ability to find closely correlated positions to Landos Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Landos Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Landos Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Landos Biopharma to buy it.
The correlation of Landos Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Landos Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Landos Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Landos Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Landos Stock
If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |